A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Sponsor
Ruijin-Hainan Hospital Shanghai Jiao Tong University School Of Medicine
Study ID
NCT05709106
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rimegepant 75 MG — DRUG
    Migraine patients would take Rimegepant 75 MG to treat or prevent a migraine attack and patients would be followed up for 1 year

Study Details

The goal of this observational study is to test the effectiveness and safety of Rimegepant in the treatment of migraine patients in real world. The main questions it aims to answer are: * \[question 1\] the effectiveness and safety of Rimegepant in the acute treatment of migraine * \[question 2\] the effectiveness and safety of Rimegepant in the long-term treatment of migraine. 1. Participants will be asked to take Rimegepant when they need to treat or prevent a migraine attack. 2. Participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any AE to evaluate the effectiveness and safety of Rimegepant in the acute treatment of migraine 3. Participants will be asked to track monthly migraine days and the use of Rimegepant, finish 2 PROs during the follow-ups, report any AE to evaluate the effectiveness and safety of Rimegepant in the long-term treatment of migraine.

Key Dates

Start date
Jan 11, 2023
Status verified
Feb 2026
Primary completion
Oct 6, 2024
Completion
Apr 9, 2025

Study Design

Enrollment
173 participants (actual)

Arms

  • Arm: Rimegepant treatment group
    this group would use Rimegepant 75mg ODT, use it when needed for 1year

Primary Outcome Measure

Change From Baseline on the percentage of participants that are pain relief at 2 hours post-dose during the migraine attack [ Time Frame: Difference between baseline and 2 hours post-dose of Rimegepant ]

Related Studies